



**Maidstone and
Tunbridge Wells**
NHS Trust

Ref: FOI/GS/ID 6569

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

08 December 2021

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to anti-VEFG treatments for eye conditions.

You asked:

1. *For the 4-month period from September to December 2020, how many patients has your trust treated with the following anti-VEGF treatments:*
 - a. *Aflibercept*
 - b. *Bevacizumab*
 - c. *Brolucizumab*
 - d. *Dexamethasone*
 - e. *Fluocinolone acetonide*
 - f. *Ranibizumab*
2. *Within your trust how many intra-vitreous injections/implants of each of the following treatments have been used in the four-month period from September to December 2020:*
 - a. *Aflibercept*
 - b. *Bevacizumab*
 - c. *Brolucizumab*
 - d. *Dexamethasone*
 - e. *Fluocinolone*
 - f. *Ranibizumab*
3. *If your trust is able to identify intra-vitreous injections/implants by eye condition, please provide the number of injections/implants used in the four-month period from September to December 2020 for each of the following conditions:*

Wet Age Related Macular Degeneration (wAMD)

 - a. *Aflibercept*
 - b. *Bevacizumab*
 - c. *Brolucizumab*

- d. Dexamethasone
 - e. Ranibizumab
- Diabetic Macular Oedema (DMO)

- a. Aflibercept
- b. Bevacizumab
- c. Dexamethasone
- d. Ranibizumab

Retinal Vein Occlusion - Central (CRVO) or Branch (BRVO)

- a. Aflibercept
- b. Bevacizumab
- c. Dexamethasone
- d. Ranibizumab

Trust response:

Please note: The way the Pharmacy data is recorded has changed. Data is now collected by finance quarter:

Q1 April, May, June

Q2 July, August, September

Q3 October, November, December

Q4 January, February, March

The following data is for April 2020 to March 2021

1.

Count of patient_hospitalno Row Labels	Column Labels			
	Q1	Q2	Q3	Q4
Aflibercept	425	798	921	985
Bevacizumab	63	62	57	67
Dexamethasone (Ozurdex)	25	57	65	33
Fluocinolone Acetonide	4	3	2	1
Ranibizumab	263	480	484	449

2.

Count of issue_type Row Labels	Column Labels			
	Q1	Q2	Q3	Q4
Ophthalmology	1388	2568	2768	2879
Aflibercept	251	1182	1623	1755
Aflibercept (Eylea)	426	244		
Bevacizumab	227	193	185	202
Dexamethasone (Ozurdex)	74	85	91	84
Fluocinolone Acetonide	6	4	3	3
Ranibizumab	404	860	866	835

3.

	Apr-Jun 20	Jul-Sep 20	Oct-Dec 20	Jan-Mar 21
afliberceptAge-related macular degeneration (disorder) (wet)	306	527	514	524
afliberceptCentral retinal vein occlusion (disorder)	32	62	55	55
afliberceptMacular edema co-occurrent and due to diabetes mellitus (disorder)	41	122	106	453
afliberceptThrombosis of retinal vein (disorder)	11	29	26	12

afliberceptVenous retinal branch occlusion (disorder)	30	45	48	195
OzurdexCentral retinal vein occlusion (disorder)	10	9	6	7
OzurdexMacular edema co-occurrent and due to diabetes mellitus (disorder)	6	10	16	11
OzurdexThrombosis of retinal vein (disorder)	2	9	7	1
OzurdexVenous retinal branch occlusion (disorder)	2	10	5	8
RanibizumabAge-related macular degeneration (disorder) (wet)	173	282	250	212
RanibizumabCentral retinal vein occlusion (disorder)	20	48	39	19
RanibizumabMacular edema co-occurrent and due to diabetes mellitus (disorder)	24	58	49	202
RanibizumabThrombosis of retinal vein (disorder)	9	27	19	9
RanibizumabVenous retinal branch occlusion (disorder)	30	52	46	117